These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26399608)

  • 1. The future of the development of medicines in idiopathic pulmonary fibrosis.
    Fregonese L; Eichler I
    BMC Med; 2015 Sep; 13():239. PubMed ID: 26399608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis.
    Nathan SD; Martinez FJ
    Curr Opin Pulm Med; 2017 Sep; 23(5):426-431. PubMed ID: 28771451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.
    Collard HR; Bradford WZ; Cottin V; Flaherty KR; King TE; Koch GG; Kolb M; Martinez FJ; Montgomery B; Raghu G; Richeldi L; Rose D; Wells AU; Brown KK
    Eur Respir J; 2015 Jul; 46(1):243-9. PubMed ID: 25900377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.
    O'Riordan TG; Smith V; Raghu G
    Chest; 2015 Oct; 148(4):1083-1092. PubMed ID: 26020856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential rules and requirements for global clinical trials in rare lung diseases: a sponsor's standpoint.
    Kuerner T
    Respir Investig; 2015 Jan; 53(1):2-6. PubMed ID: 25542597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
    Moodley Y; Corte T; Richeldi L; King TE
    Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.
    Vaidya B; Patel R; Muth A; Gupta V
    Curr Med Chem; 2017; 24(22):2439-2458. PubMed ID: 28552057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IPF clinical trial design and endpoints.
    Nathan SD; Meyer KC
    Curr Opin Pulm Med; 2014 Sep; 20(5):463-71. PubMed ID: 25022315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research.
    Baroke E; Gauldie J; Kolb M
    Expert Rev Respir Med; 2013 Oct; 7(5):465-78. PubMed ID: 24138691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review.
    Fois AG; Paliogiannis P; Sotgia S; Mangoni AA; Zinellu E; Pirina P; Carru C; Zinellu A
    Respir Res; 2018 Mar; 19(1):51. PubMed ID: 29587761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis: current and future directions.
    Soo E; Adamali H; Edey AJ
    Clin Radiol; 2017 May; 72(5):343-355. PubMed ID: 28118995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
    Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
    Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.
    Nair GB; Matela A; Kurbanov D; Raghu G
    Expert Rev Respir Med; 2016 Jun; 10(6):699-711. PubMed ID: 27094006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pulmonary fibrosis: an Australian perspective.
    Prasad J; Holland AE; Glaspole I; Westall G
    Intern Med J; 2016 Jun; 46(6):663-8. PubMed ID: 27257148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current clinical trials for the treatment of idiopathic pulmonary fibrosis.
    Klingsberg RC; Mutsaers SE; Lasky JA
    Respirology; 2010 Jan; 15(1):19-31. PubMed ID: 20199632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.